Oct 15 2015
Nanovis, a life sciences company committed to developing scientifically advanced regenerative platforms for implantable medical devices, today announced the availability of the FortiCore wedge shaped lordotic cervical cage and a transforaminal lumbar interbody fusion (TLIF) device with increased scaffolding.
Nanovis' FortiCore implants combine the benefits of PEEK and titanium creating the most scientifically advanced interbody fusion devices. The launch of the wedge shaped cervical cage and TLIF follows the completion of more than 400 FortiCore implantations by leading surgeons at hospitals throughout the United States.
FortiCore interbody fusion devices are comprised of a PEEK center with a deeply porous titanium scaffold. PEEK Optima® by Invibio is also injection molded into the scaffold for exceptional integration. This unique combination of technologies is designed to increase positive outcomes in spinal fusion procedures with the imaging capabilities preferred by surgeons.
"Hospitals that are focused on outcomes and quality of care want interbody devices that allow surgeons to improve fusion and stabilization rates. This requires a different approach. A scientifically advanced approach that is fundamentally different from legacy titanium, PEEK, and surface coated implants," said Matt Hedrick, CEO, Nanovis. "FortiCore isn't a chip off the old block. We've layered a deeply porous titanium scaffold on PEEK creating fundamentally differentiated implants. That is uniquely FortiCore and this differentiation is only the beginning. At Nanovis, we continually invest in science that advances innovation to the surface to revolutionize implants."
Nanovis' FortiCore interbody fusion devices include cervical and TLIF implants complemented by the FortiFix pedicle screw system and FortiBridge cervical plate system. Nanovis is featuring FortiCore at the 2015 North American Spine Society (NASS) meeting in Chicago, November 14-17, at the Nanovis booth (#1779).
SOURCE Nanovis
Critical gaps found in pediatric medical device trials: Lack of control groups and low infant participation